Last reviewed · How we verify

NCT06085781: HN-BIO

A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers

Recruiting now NA Last updated 5 March 2026
What this trial tests

NA trial testing fMRI in Squamous Cell Carcinoma of Head and Neck in 60 participants. Currently enrolling.

Timeline
29 January 2024
Primary endpoint
15 January 2027
15 January 2027

Quick facts

Lead sponsorUniversity Health Network, Toronto
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment60
Start date29 January 2024
Primary completion15 January 2027
Estimated completion15 January 2027
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Squamous Cell Carcinoma of Head and Neck. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore biomarker development in patients with newly diagnosed Head and neck squamous cell carcinoma (HNSCC) receiving curative therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of fMRI

Trials testing the same drug.

Other recruiting trials for Squamous Cell Carcinoma of Head and Neck

Currently open trials in the same condition.

Other University Health Network, Toronto trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06085781.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing